Seleno L-methionine acts on cyclophosphamide-induced kidney toxicity by Ayhancı, Adnan et al.
Seleno L-Methionine Acts on Cyclophosphamide-Induced
Kidney Toxicity
Adnan Ayhanci & Sibel Günes & Varol Sahinturk &
Sila Appak & Ruhi Uyar & Mustafa Cengiz &
Yilmaz Altuner & Suzan Yaman
Received: 29 August 2009 /Accepted: 23 September 2009 /
Published online: 14 October 2009
# Humana Press Inc. 2009
Abstract The anticancer drug cyclophosphamide (CP) has nephrotoxic effects besides its
urotoxicity, which both in turn limit its clinical utility. The nephrotoxicity of CP is less
common compared to its urotoxicity, and not much importance has been given for the study
of mechanism of CP-induced nephrotoxicity so far. Overproduction of reactive oxygen
species (ROS) during inflammation is one of the reasons of the kidney injury.
Selenoproteins play crucial roles in regulating ROS and redox status in nearly all tissues;
therefore, in this study, the nephrotoxicity of CP and the possible protective effects of
seleno L-methionine (SLM) on rat kidneys were investigated. Forty-two Sprague–Dawley
rats were equally divided into six groups of seven rats each. The control group received
saline, and other rats were injected with CP (100 mg/kg), SLM (0.5 or 1 mg/kg), or CP+
SLM intraperitoneally. Malondialdehyde (MDA) and glutathione (GSH) levels in kidney
homogenates of rats were measured, and kidney tissues were examined under the
microscope. CP-treated rats showed a depletion of renal GSH levels (28% of control),
while CP+SLM-injected rats had GSH values close to the control group. MDA levels
increased 36% of control following CP administration, which were significantly decreased
after SLM treatment. Furthermore, these biochemical results were supported by
microscopical observations. In conclusion, the present study not only points to the
therapeutic potential of SLM in CP-induced kidney toxicity but also indicates a significant
role for ROS and their relation to kidney dysfunction.
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Introduction
Cyclophosphamide (CP) is a drug with a wide spectrum of clinical uses, and it has been
proved to be effective in the treatment of cancer (lymphoma, acute and chronic leukemias,
and multiple myeloma) and non-malignant disease states such as rheumatoid arthritis [1].
However, this drug may induce acute inflammation in the urinary bladder (cystitis) and
causes renal damage [2, 3] and liver damage [4], thereby limiting its therapeutic window.
Ifosfamide and CP have to be activated through a metabolic step in vivo in which numerous
metabolites are known [5]. Studies have shown that CP can also cause nephrotoxicity
besides its urotoxic effects [3, 4]. The nephrotoxicity of CP was generally overlooked
because plasma creatinine, an indicator of glomerular function of the kidney, is not altered
significantly in patients on CP chemotherapy. However, in a recent study, Sugumar et al. [6]
have demonstrated in a rat model that CP induces renal damage microscopically but a
reliable biochemical marker of renal dysfunction, the plasma creatinine, remained unaltered.
CP can result in glomerular dysfunction and tubular dysfunction [6, 7]. The nephrotoxicity
is considered to be dose dependant and includes a variable reduction of glomerular filtration
rate along with tubular dysfunction.
Phosphoramide mustard (PAM) and acrolein (ACR) are two active metabolites of
cyclophosphamide produced by the liver microsomal enzymes [8]. Cyclophosphamide’s
antineoplastic effects are associated with PAM, while ACR is linked with its toxic side
effects. ACR interferes with the tissue antioxidant defense system [9], produces highly
reactive oxygen-free radicals [10], and are mutagenic to mammalian cells [11]. Antioxidant
agents like amifostine, a thiol antioxidant, have cytoprotective action against platinum-
induced renal toxicity. However, amifostine is not used due to its toxic effects: hypocalcaemia,
anxiety, and hypotension [12].
Seleno L-methionine is a nutritionally essential trace element representing the
major nutritional source of selenium for higher animals and humans [13]. Se is a
constituent of glutathione peroxidase (GSH-Px), an enzyme that uses glutathione (GSH)
to remove hydrogen peroxide as well as fatty acid hydroperoxides, thereby preventing
hydroxyl radical formation [14]. The level of MDA, a marker of lipid peroxidation,
was found to be higher in tumor than in non-tumor tissues [15]. Selenium was found to
be highly protective against toxicity induced by a variety of chemotherapeutic agents
[16]. The aim of the present study was to investigate the potential protective effects of
pharmacological dosages of seleno L-methionine against CP-induced kidney damage in
rats.
Materials and Methods
Chemicals and Drugs
CP (Endoxan, Cyclophosphamide Monohydrate, C0768) was purchased from Sigma-
Aldrich, Taufkirchen, Germany. Se (Seleno-L-Methionine, S3132) was purchased from
Sigma, Germany.
172 Günes et al.
Experimental Protocol
A total of 42 Sprague–Dawley rats of either sex, 200±20 g, were provided by the
Experimental Animal Research Facility, Eskisehir Osmangazi University, Eskisehir, Turkey.
The rats were housed under conditions of controlled temperature (22°C) and acclimatized to
12:12 h light/dark cycle. Animals were given food and water ad libitium. Animal experiments
were conducted according to the guidelines of Institutional Animal Ethics Committee (Date-
Protocol no: 16.06.2009-117/2009).
The rats were randomly divided into the following experimental groups, each including
seven animals: Group 1 served as the vehicle (normal saline) treated controls. Group 2
animals received CP i.p. dissolved in saline, in a single dose of 100 mg/kg b.w. Groups 3
and 4 were treated with 0.5 or 1 mg/kg seleno L-methionine (SLM) for six consecutive
days. The animals of group 5 or 6 received respective SLM for 6 days and then a single
dose of CP administered on the fourth day [17]. Animal groups and their treatments are
summarized in Table 1.
Sample Collection and Biochemical Assays
All animals were anesthetized with an i.p. injection of 60 mg sodium pentobarbitone per
kilogram of b.w. and then killed by cervical dislocation 24 h after the final saline, CP, or
SLM injections. The kidneys were removed intact, washed with saline, and blotted dry on a
filter paper. The kidneys were then cut into two equal pieces. One half was stored at −20°C
to measure kidney MDA and GSH contents; the rest was fixed for 24 h in 10% buffered
formaldehyde (Table 2).
Histological Procedures
For light microscopy, tissues were processed routinely for paraffin embedding, and 5-μm
serial cross sections were stained and examined for the presence of necrosis, edema,
Table 1 Groups of Rats (n=7) and Their Treatments
Groups Days
1 2 3 4 5 6 7
Control Saline Saline Saline Saline Saline Saline X
CP Saline Saline Saline CP Saline Saline X
0.5 SLM SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
X
1 SLM SLM
(1 mg/kg)
SLM
(1 mg/kg)
SLM
(1 mg/kg)
SLM (1 mg/kg) SLM
(1 mg/kg)
SLM
(1 mg/kg)
X
CP+0.5
SLM
SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
+CP
SLM
(0.5 mg/kg)
SLM
(0.5 mg/kg)
X
CP+1
SLM
SLM
(1 mg/kg)
SLM
(1 mg/kg)
SLM
(1 mg/kg)
SLM (1 mg/kg)
+CP
SLM
(1 mg/kg)
SLM
(1 mg/kg)
X
CP cyclophosphamide (100 mg/kg), SLM seleno L-methionine, X killed
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hemorrhage, tubular degeneration, mononuclear/polimorphonuclear cell infiltration, and
narrowing of Bowman’s capsule space [18].
Malondialdehyde
MDA content was measured as described by Ohkawa et al. in 1979 [19]. Kidney tissues
were homogenized in appropriate buffers and used for the following assays. The mixture
consisted of 0.8 ml of sample (1 mg), 0.2 ml of 8.1% sodium dodecylsulfate, 1.5 ml of 20%
glacial acetic acid adjusted to pH=3.5, and 1.5 ml of 0.8% aqueous solution of
thiobarbituric acid. The mixture was diluted to 4 ml with distilled water and heated at
95°C for 60. Distilled water (1 ml) and 5 ml n-butanol and pyridine mixture (15:1) were
added and centrifuged at 2,000×g for 10 min. The absorbance of the organic layer was
measured at 532 nm. Amount of thiobarbituric reacting substances formed is calculated
from standard curve prepared using 1, 1′, 3, 3′ tetramethoxy propane, and the values were
expressed as nmol MDA/g tissue.
Glutathione
Tissue levels of acid-soluble thiols, mainly GSH, were determined colourimetrically at
412 nm. Briefly, 0.5 ml of the previously prepared homogenate was added to 0.5 ml of 5%
trichloroacetic acid, and after centrifugation at 750×g for 5 min, the supernatant (200 μl)
was added to a tube containing 1,750 μl of 0.1 mol/l potassium phosphate buffer, pH=8,
and 50 μl 5,5′-dithiobis-(2-nitrobenzoic acid) reagent. Tubes were mixed, and the yellow
color that developed was measured against a standard curve of GSH. The protein thiol
(protein-SH) content was expressed as μmol/g of tissue.
Statistics
The results were expressed as means ± SD and p<0.05 accepted as statistically significant.
Statistical analyses were performed using one-way analysis of variance for MDA and GSH
levels. The Tukey’s test was then performed to analyze the two groups consecutively.
Table 2 MDA and GSH Levels in Kidney Tissue of Rats Treated with CP, SLM, and SLM Followed by CP
Groups (n=7) MDA (nmol/g protein) GSH (µmol/g protein)
Control 14.22±1.36 38.20±1.66
CP 22.17±1.25a 27.79±0.97a
0.5SLM 14.35±0.93b,c 40.81±2.14a,b,c
1SLM 14.81±0.79b,d 41.14±1.36a,b,d
CP+0.5SLM 17.36±1.13a,b 36.86±0.88b
CP+1SLM 19.37±0.96a,b,c 36.87±1.12b
Values are shown as mean ± SD
a Significantly different from controls (p<0.05)
b Significantly different from CP group (p<0.05)
c Significantly different from CP+0.5 SLM group (p<0.05)
d Significantly different from CP+1 SLM group (p<0.05)
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Results
Biochemical Results
CP significantly increased MDA relative to the control (36%, p<0.05), which was sig-
nificantly restored in the kidneys of the animals pretreated with SLM (0.5 or 1 mg/kg/day)
as opposed to those receiving only CP tissue (see Fig. 1). CP also produced a significant
reduction in GSH (28%) of the kidney relative to the control (p<0.05). Groups receiving
SLM (0.5 or 1 mg/kg/day) showed a significant restoration in GSH concentration of the
kidney. The group of rats having SLM alone showed no significant alteration in the levels
of MDA and GSH (see Fig. 2).
Microscopic Evaluation
Microscopical observations also provided supportive evidence for the biochemical results
as seen in Fig. 3. Medullar regions showed normal histology in all sections of the groups.
The kidneys of the control and the groups having SLM alone showed normal histology.
Kidney tissues of CP-administered rats showed desquamation of tubular epithelial cells
with accumulation of eosinophilic granular material within the lumen of the tubules and
narrowing of Bowman’s capsule spaces. In the CP+SLM groups, SLM decreased the
degeneration of the tubules and the kidney corpuscles looked normal.
Discussion
CP has been associated with various kinds of urinary tract toxicities [20, 21], but kidney
toxicity has only rarely been reported. In 1961, Philips et al. reported that renal papillary
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Fig. 1 MDA levels of the kidney. CP administration significantly increased MDA level relative to the
control (36%), which was significantly restored kidney in animals pretreated with SLM (0.5 or 1 mg/kg/day)
as opposed to those receiving only CP tissue (p<0.05)
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necrosis had developed after a single i.p. injection of CP (222 mg/kg) in male rats [22].
Since then, there have been a few publications concerning the nephrotoxicity of CP in
animal experiments, but these have only mentioned renal tubular necrosis [23] or
glomerular changes [24].
In the present study, it was shown that treatment with only CP caused nephrotoxicity in
rats, as evidenced by the high biochemical parameters such as high lipid peroxidation
(MDA) and low antioxidant activity (GSH) and by histological changes as well. Many
studies have reported structural changes in the kidney [5, 25, 26]. The level of kidney MDA
in the CP-treated group was significantly higher compared with their levels in the controls.
Increased MDA (36%) levels indicated that lipid peroxidation, mediated by ROS, was an
important contributing factor in the development of CP-mediated tissue damage (p<0.05).
However, pretreatment with SLM significantly prevented CP-induced lipid peroxidation in
the kidney tissues, implicating an antioxidant effect from this trace element. This was
probably due to less damage having occurred from oxygen-free radicals.
GSH is the most important molecule for maintaining cell integrity and participation in
cell metabolism [27]. The significant reduction in GSH levels promoted by CP represents
an alteration in the cellular redox state, suggesting that the cells could be more sensitive to
ROS. This leads to a reduction in effectiveness of the antioxidant enzyme defense system
[28]. In this study, GSH levels in the kidney tissues of rats treated with CP were lower
(28%) than the control groups (p<0.05). On the other hand, an increase in GSH levels in
the kidney tissues indicated that pretreatment with SLM caused the increase as a response
to oxidative stress.
Se is recognized to have a capacity for conferring tolerance to the toxic manifestations of
various heavy metal exposures, including cadmium, mercury, lead, and arsenic [29, 30] in
addition to role as an anticancer agent [31]. Moreover, Se has protective effects against
mercury toxicity in rat kidney and Se also used to diminish the toxic effects of the cadmium
on the antioxidant enzyme system, which in turn affects the membranes structures such as
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Fig. 2 CP produced a significant reduction in GSH level (28%) in the kidney relative to the control (p<0.05).
Groups receiving SLM (0.5 or 1 mg/kg/day) showed a significant restoration in GSH concentration in the
kidney (p<0.05)
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mitochondria and endoplasmic reticulum. On the other hand, Se deficiency reducing GSH-
Px activity has been reported in the diet of glomerular disease and in the diet of tubular
epithelium in normal rats [32]. Concurrent or prior injections of Se were found to protect
against many of the acute effects of cadmium, e.g., testicular necrosis, placental hemorrhage,
teratogenecity, and damage to the lactating mammary glands [31–34].
These results correlated well with the microscopical results from the kidneys, which
revealed tubular necrosis in the renal cortex. The kidneys of the control and SLM groups
Fig. 3 Micrographs of kidney cortexes of the rats from a control, b 0.5 SLM, and c 1 SLM groups showing
normal histology; d CP group showing degenerated tubules (black arrows) and narrowing of Bowman’s
capsule spaces (white arrows); e CP+0.5 SLM and f CP+1 SLM showing almost normal architecture. All
sections were stained with H&E
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showed normal histology. However, rats given CP had a moderately severe glomerular
congestion and degeneration and dilatation in Bowman’s space and in the collective tubules
in the kidney sections. On the other hand, the tubule cells from rats in the CP+SLM groups
were nearly normal in histological architecture, except for a minor desquamation of the
kidney epithelial cells. Similar findings were also reported by Tripathi and Jena [35], and
Babu et al. [25], demonstrating the structural changes in the kidney tissues of CP-treated
animals and its healing by different agents.
In this study, we have shown that experimental CP administration caused an increase in
lipid peroxidation in rats, which we believe is a result of the oxidative stress caused by CP,
and SLM can act as a protective pharmacological agent or decrease the side effects of CP-
induced kidney toxicity.
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